Genprex Inc (GNPX) concluded trading on Thursday at a closing price of $0.33, with 8.53 million shares of worth about $2.82 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -69.73% during that period and on May 29, 2025 the price saw a gain of about 18.89%. Currently the company’s common shares owned by public are about 27.82M shares, out of which, 27.06M shares are available for trading.
Stock saw a price change of 19.74% in past 5 days and over the past one month there was a price change of 18.93%. Year-to-date (YTD), GNPX shares are showing a performance of -60.90% which decreased to -84.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $4.09 during that period. The average intraday trading volume for Genprex Inc shares is 4.59 million. The stock is currently trading 20.13% above its 20-day simple moving average (SMA20), while that difference is up 15.46% for SMA50 and it goes to -51.53% lower than SMA200.
Genprex Inc (NASDAQ: GNPX) currently have 27.82M outstanding shares and institutions hold larger chunk of about 1.52% of that.
The stock has a current market capitalization of $9.26M and its 3Y-monthly beta is at -0.47. It has posted earnings per share of -$4.92 in the same period. It has Quick Ratio of 1.94 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GNPX, volatility over the week remained 8.03% while standing at 8.13% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by National Securities on January 26, 2021 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by Noble Capital Markets stated Genprex Inc (GNPX) stock as an Outperform in their note to investors on April 29, 2019, suggesting a price target of $5 for the stock.
